Phloroglucinol

Market Dynamics Intelligence, Analysis, and Forecast for Resorcinol

I. Market Dynamics Intelligence
1. Price Trend
As of July 21, 2026, the B2B benchmark price for m-aminophenol (one key raw material for resorcinol) reported by Shengyishe is RMB 24,433.33 per metric ton—unchanged from early July and June levels. The average price over the past three months stands at RMB 24,438/ton, with a fluctuation range of RMB 24,433–24,467/ton—representing the lowest level within the past year. On February 26, 2026, the benchmark price peaked at RMB 24,966.67/ton but subsequently declined to the current level due to supply-demand rebalancing.

2. Supply-Demand Situation
Supply: Domestic resorcinol production capacity is relatively high, resulting in structural overcapacity. Effective annual capacity is approximately 840 metric tons. Leading manufacturers have adopted continuous-process manufacturing technologies to significantly reduce waste emissions, partially offsetting raw material cost pressures and thereby improving capacity utilization. However, the exit of small- and medium-sized enterprises (SMEs) may cause localized supply tightness; overall, supply remains comparatively stable, supported by capacity expansions from industry leaders.
Demand: Driven by population aging and rising incidence of spastic conditions, demand for antispasmodic drugs continues to grow steadily. As a key active pharmaceutical ingredient (API) in antispasmodics, resorcinol benefits from this trend. China’s domestic resorcinol output increased from 528 tons in 2017 to approximately 700 tons in 2021. Additionally, R&D breakthroughs in pharmaceutical applications and expanding export opportunities—especially in emerging markets such as Southeast Asia and South America—are further bolstering demand. China’s resorcinol export volume is projected to reach 25,000 tons in 2025.

3. Competitive Landscape
Resorcinol Injection: The most widely used and broadly indicated antispasmodic in clinical practice, facing intense competition. As of 2024, approximately 26 pharmaceutical companies hold marketing authorizations for resorcinol injection in China. In 2023, total terminal sales revenue for resorcinol injection in the domestic healthcare market reached RMB 821 million. The top four market players were Nanjing Hengsheng Pharmaceutical Co., Ltd. (62.39%), Wanbangde Pharmaceutical Group Co., Ltd. (27.83%), Wuhan Humanwell Pharmaceutical Co., Ltd. (9.74%), and Chengdu Betta Pharmaceutical Co., Ltd. (0.04%). As of July 2026, Sinopharm Group Guorui Pharmaceutical has successfully obtained marketing authorization for this product.
Raw Material Supply: Fewer than ten Chinese enterprises hold GMP certification for resorcinol API manufacturing. Two leading firms—a prominent Jiangsu-based fine chemical and pharmaceutical intermediate enterprise and a major Zhejiang-based specialty chemical company—collectively command over 70% of the domestic API market share, indicating an exceptionally concentrated upstream supply structure.

4. Policy Impacts
The National Medical Products Administration (NMPA) has mandated revisions to the package insert for resorcinol injection products, requiring marketing authorization holders to file updated labeling and prescribing information and strengthen education and training on newly identified adverse drug reactions. This may influence prescriber and patient decision-making, thereby affecting demand patterns.
The National Healthcare Security Administration (NHSA) continues advancing implementation of centralized volume-based procurement (VBP) outcomes, promoting broader access—including into primary care facilities and retail pharmacies. As a priority VBP candidate, resorcinol injection faces significant pricing and market-share reallocation pressure under this policy framework.

II. Analytical Assessment
1. Pricing Outlook
Short Term: Resorcinol API prices are expected to remain range-bound between RMB 24,400–24,500/ton. Supply-demand equilibrium and cost pressures will counterbalance each other: capacity expansion by leading producers eases supply constraints, while sustained pharmaceutical demand provides upward support—limiting both downside and upside potential.
Long Term: Should global pharmaceutical R&D yield breakthroughs (e.g., next-generation antiviral therapeutics) or unexpected surges in adjacent industrial demand (e.g., electric vehicle battery materials), resorcinol prices could rise above RMB 25,000/ton. Conversely, declines in upstream feedstock costs (e.g., crude oil or natural gas prices) or rapid capacity ramp-up (e.g., Jianxin Pharmaceuticals’ new facility coming online) could push prices modestly downward toward RMB 24,000/ton.

2. Competitive Dynamics
Competition in the resorcinol injection market will intensify further. With additional entrants securing approvals, market share battles will escalate. Under VBP, price competition will dominate; manufacturers must enhance operational efficiency and reduce unit costs to remain competitive. Concurrently, product quality, brand equity, and distribution network strength will increasingly shape long-term market positioning.
Upstream API supply concentration implies closer strategic collaboration between formulation manufacturers and API suppliers. Formulators may deepen involvement in API process optimization or enter long-term supply agreements to secure reliable, high-quality raw material sourcing and mitigate supply-chain disruption risks.

3. Regulatory Impact Assessment
VBP policies will continue exerting profound influence. Further price compression and margin erosion are inevitable, yet volume-driven commercial opportunities will expand accessibility and usage frequency. Enterprises must proactively adapt their manufacturing and commercial strategies—emphasizing cost-effectiveness and value optimization—to sustain competitiveness in VBP tenders.
Revised labeling requirements will compel manufacturers to strengthen pharmacovigilance and clinical evidence generation related to safety and efficacy. While enhancing public health protection and market standardization, these measures may increase R&D and compliance expenditures.

III. Forward-Looking Forecast
1. Price Forecast
Over the next 12 months, resorcinol API prices are highly likely to remain within the RMB 24,400–24,500/ton band, exhibiting limited volatility. Significant positive or negative external shocks—such as regulatory breakthroughs or geopolitical supply disruptions—could induce moderate deviations from this range, though sustained breaches above RMB 24,500 or below RMB 24,400 appear improbable.

2. Market Structure Forecast
Market concentration in the resorcinol injection segment is expected to increase further. Under combined VBP and competitive pressures, smaller, less-efficient players may gradually exit, consolidating market share among industry leaders. Firms possessing vertically integrated capabilities, sustained innovation pipelines, and digitally enabled operational excellence will gain decisive competitive advantage.
The API supply landscape will remain largely stable. High regulatory barriers to entry—including stringent GMP, environmental, and technical qualification requirements—will deter new entrants. Incumbent leaders will retain dominance, though competition may shift toward process innovation, cost leadership, and quality consistency enhancement.

3. Policy Impact Forecast
VBP implementation will become increasingly institutionalized, broadening both product scope and geographic coverage. Resorcinol injection pricing will continue declining incrementally; enterprises must continuously optimize cost structures and improve productivity to meet VBP benchmarks. Simultaneously, VBP will incentivize quality upgrading and therapeutic equivalence validation, fostering industry-wide advancement.
Regulatory oversight will tighten progressively, with heightened emphasis on robust clinical evidence, comprehensive risk management, and strict quality control throughout the product lifecycle. Companies must prioritize R&D investment in safety/efficacy profiling and quality-by-design principles to ensure full compliance with evolving regulatory expectations.